database > company

NeoStem
HCID Member | Biotech Specialty Pharma
420 Lexington Avenue Suite 450
New York, NY 10170 USA
phone:212-584-4180
fax:646-514-7787
Symbol NBS
Exchange AMEX
Founded 2006
Employees 600
          www.neostem.com
Research Sector Biotech Specialty Pharma
Summary Description
International biopharmaceutical company with product and service revenues, global research and development capabilities and operations in three distinct business units.
Management
Robin Smith, MD MBA, CEO & Chairman of the Board;
Jian Zhang, General Manager;
Peter Sun, MD General Manager;
Larry May, Chief Financial Officer;
Chris Duignan, CPA, Chief Accounting Officer & VP of Finance;
Catherine Vaczy, ESQ, VP and General Counsel;
Alan Harris, MD PhD FACP FRCP, VP of Drug Development and Regulatory Affairs;
Anthony Salerno, VP of Strategic Development and Academic Affairs
Ownership
Financials Mkt Cap :17


* numbers in thousands

 
Keywords
peripheral, vascular, congestive, mycardial, cardiac


Comment | Printable Version | Modify profile Aug. 28, 2010

Description
NeoStem, Inc. is an international biopharmaceutical company with product and service revenues, global research and development capabilities and operations in three distinct business units: (i) U.S. adult stem cells, (ii) China adult stem cells, (iii) China pharmaceuticals. These business units are expected to provide platforms for the accelerated development and commercialization of innovative technologies and products in both the U.S. and China.
Products / Services
Stem Cell Therapy

Stem Cell Banking

Manufacturing of Generic Pharmaceuticals

Technology / Differentiation
Various licensed adult stem cell technologies, including a worldwide exclusive license to VSEL(TM) Technology which uses very small embryonic stem cells.
Market / Customers
Adults in US & China

Over 150 Billion Dollars annual business worldwide stem cell therapy and pharmaceuticals in China

Status
Revenue generating with drugs in pipeline, clinical trials and mature stem cell therapy with early stage stem cell research and development.